NCT05236881 (ANíMATE) is a NA clinical trial of ANíMATE mobile application in Obesity, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

Who is sponsoring NCT05236881?

NCT05236881 is sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.

What drugs are being tested in NCT05236881?

Interventions in NCT05236881: ANíMATE mobile application.

Is NCT05236881 still recruiting?

NCT05236881 is currently completed. Last updated 18 November 2025.

Last reviewed 2025-11-18 · How we verify

NCT05236881: ANíMATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of an mHealth Tool (ANíMATE) to Assess Self-management, Self-care and Adherence in People With Obesity

Completed NA Last updated 18 November 2025

What this trial tests

NA trial testing ANíMATE mobile application in Obesity in 36 participants. Completed in 31 January 2025.

Timeline

20 April 2022

Primary endpoint
13 November 2024

31 January 2025

Quick facts

Lead sponsor	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	20 April 2022
Primary completion	13 November 2024
Estimated completion	31 January 2025
Sites	1 location across Spain

Drugs / interventions tested

ANíMATE mobile application

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Who can join

Adults 18 to 100, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial main purpose is to develop and test an mHealth app aimed at improving self-management, self-care and adherence of people with obesity. The study population are type I or II obese people, aged more than 18 years old, with or without comorbidities, who have a smartphone or tablet compatible with the app (Android version 9.0 or higher) and access to a scale for regular weight monitoring. Control group will follow standard care protocol and patients in the intervention group will also be provided with the app. Follow-up will be done for 16 weeks. Both groups will attend 3 face-to-face visits (baseline, 2 and 4 months).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mobile health (m-health) smartphone interventions for adolescents and adults with overweight or obesity.
Metzendorf MI, Wieland LS, Richter B. · · 2024 · cited 28× · PMID 38375882 · DOI 10.1002/14651858.cd013591.pub2

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau trials

Trials by the same sponsor.

NCT07343882 — Quantification of Systemic Congestion by Ultrasound As a Predictor of Weaning Failure From Mechanical Ventilation · NA · not yet recruiting
NCT07530237 — Efficacy of Periarticular Vasoconstrictor Infiltration (PVI) in Reducing Bleeding and Postoperative Pain in Lumbar Fusio · active not recruiting
NCT07369310 — Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming · NA · not yet recruiting
NCT07314190 — Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodege · enrolling by invitation
NCT07239843 — Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychia · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05236881 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Last refreshed: 18 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05236881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing